Escherichia coli Isolate with MCR-1 Gene for Diagnostic Test Development

This technology includes Escherichia coli isolate with MCR-1 gene which can be used in the development of diagnostic tests. The MCR-1 gene makes bacteria resistant to the antibiotic colistin, which is used as a last-resort drug to treat patients with multi-drug-resistant infections, including carbapenem-resistant Enterobacteriaceae (CRE). This gene exists on a plasmid, a small piece of DNA that is capable of moving from one bacterium to another, spreading antibiotic resistance among bacterial species.

Novel Reassortant Mammalian Orthoreovirus Isolate for the Development of Vaccines and Diagnostic Tools

This technology includes a novel, isolated reassortant mammalian Orthoreovirus (MRV) isolated from pigs with neurological symptoms, for use in the development of vaccines and diagnostic tests. This isolate has S1 gene from MRV1 closed to bovine isolated, M2 gene from MRV2 and other 8 genes from MRV3 based on full-genome sequence analysis. MRV3 has been reported and isolated from the US pigs with diarrhea symptom. Compared to the reported swine MRV3 isolates that cause diarrhea in pigs, the novel reassortant MRV causes neurological disease in pigs.

Protecting Healthcare Workers by Detecting Contamination From Hazardous Antineoplastic Drugs

FLC logo

CDC NIOSH early technology to detect surface contamination by hazardous antineoplastic drugs. Antineoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. While these drugs are lifesaving to patients, they must be handled with care by healthcare workers. Exposure from contaminated surfaces and drug vials can cause skin problems, birth defects, reproductive issues, and increased risk of various cancers.

Protecting Healthcare Workers by Detecting Contamination From Hazardous Antineoplastic Drugs

FLC logo

CDC NIOSH early technology to detect surface contamination by hazardous antineoplastic drugs. Antineoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. While these drugs are lifesaving to patients, they must be handled with care by healthcare workers. Exposure from contaminated surfaces and drug vials can cause skin problems, birth defects, reproductive issues, and increased risk of various cancers.

CDC’s Assay for Global Surveillance of Drug-resistant HIV-1 Was Commercialized

FLC logo

Researchers at the Centers for Disease Control and Prevention (CDC) developed a low-cost technology to rapidly detect HIV-1 drug resistance (HIVDR) in plasma and dried blood spot (DBS) samples with 95.8% genotyping sensitivity. CDC’s partners at Life Technologies Corporation (“LifeTech”) have licensed, further developed, and incorporated the technology into a commercialized product. Life Tech’s HIV-1 Genotyping Kit provides a cost-effective assay, scalable workflow, easy-to read sequencing results, and robust test performance.

SARS-CoV-2 Virus Specimen and Material Sharing

FLC logo

The Centers for Disease Control and Prevention (CDC) and the National Institute for Allergy and Infectious Diseases (NIAID) have been rewarded for their partnership from the 2021 Federal Laboratory Consortium (FLC) awards. The CDC and NIAID had already developed a new approach to sharing samples during a Public Health Emergency of International Concern (PHEIC) during the Zika pandemic, which enabled them to respond quickly and efficiently to access and share samples of SARS-CoV-2 early in the outbreak.

Patrick McCue

Dr. McCue joined OTT in June 2009. Prior to joining OTT, Dr. McCue was a technology transfer fellow at the National Cancer Institute (NCI)’s Technology Transfer Center. Dr. McCue completed research fellowships at the NCI-Frederick, at the National Center for Complementary and Alternative Medicine (NCCAM), and at the Genome Research Facility of the National Aeronautics and Space Administration (NASA). Registered to practice before the U.S. Patent and Trademark Office, Dr.

Subscribe to CDC